Published in Women's Health Weekly, August 11th, 2005
Twinject, an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was approved by the U.S. Food and Drug Administration (FDA) in 2003; 2 dosages are now approved for self-administration (0.3 mg and 0.15 mg). In addition to Twinject, Verus has acquired rights to other intellectual property and assets, including complementary and next generation device designs and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly